Financing ·
Fate Therapeutics establishes $100M at-the-market equity offering program with Leerink Partners
FATEFate Therapeutics Inc
Fate Therapeutics entered into a Sales Agreement with Leerink Partners to establish an at-the-market (ATM) offering program allowing the company to sell up to $100 million of its common stock. The firm will act as sales agent, receiving a commission of up to 3.0% on gross proceeds. Concurrently, Fate terminated its prior ATM agreement with Jefferies, under which it had sold approximately 2.8 million shares for $8.0 million in gross proceeds since November 2023. The company operates in the biotechnology industry, focusing on developing cellular immunotherapies.